Kidney and Cardiovascular Effectiveness of SGLT2 Inhibitors Compared with GLP-1 Receptor Agonists in Patients with Type 2 Diabetes

被引：0
|
作者：
Edmonston, Daniel
Mulder, Hillary
Lydon, Elizabeth
Chiswell, Karen
Lampron, Zachary
Shay, Christina M.
Marsolo, Keith
Bosworth, Hayden B.
Pagidipati, Neha
机构：
来源：
DIABETES | 2024年 / 73卷
关键词：
D O I：
10.2337/db24-912-P
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
912-P
引用
收藏
页数：2
相关论文
共 50 条
  • [11] Race and ethnicity and pharmacy dispensing of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Rodriguez, Luis A.
    Finertie, Holly
    Neugebauer, Romain S.
    Gosiker, Bennett
    Thomas, Tainayah W.
    Karter, Andrew J.
    Gilliam, Lisa K.
    Oshiro, Caryn
    An, Jaejin
    Simonson, Gregg
    Cassidy-Bushrow, Andrea E.
    Dombrowski, Sarah
    Nolan, Margaret
    O'Connor, Patrick J.
    Schmittdiel, Julie A.
    LANCET REGIONAL HEALTH-AMERICAS, 2024, 34
  • [12] SGLT-2 inhibitors and GLP-1 receptor agonists for Type 2 diabetes
    Davila, Esteban
    Mccormack, James
    ACADEMIC EMERGENCY MEDICINE, 2024, 31 (04) : 408 - 411
  • [13] SGLT2 inhibitors and GLP-1 receptor agonists: the definitive combination?
    Cervantes, Carlos Escobar
    LANCET DIABETES & ENDOCRINOLOGY, 2024, 12 (08): : 507 - 508
  • [14] GLP-1 receptor agonists and SGLT2 inhibitors: a couple at last?
    Nauck, Michael A.
    Meier, Juris J.
    LANCET DIABETES & ENDOCRINOLOGY, 2016, 4 (12): : 963 - 964
  • [15] SGLT2 inhibitors and GLP-1 receptor agonists: a sound combination
    De Block, Christophe
    LANCET DIABETES & ENDOCRINOLOGY, 2018, 6 (05): : 349 - 352
  • [16] Primary Prevention of Cardiovascular and Heart Failure Events With SGLT2 Inhibitors, GLP-1 Receptor Agonists, and Their Combination in Type 2 Diabetes
    Wright, Alison K. K.
    Carr, Matthew J. J.
    Kontopantelis, Evangelos
    Leelarathna, Lalantha
    Thabit, Hood
    Emsley, Richard
    Buchan, Iain
    Mamas, Mamas A. A.
    van Staa, Tjeerd P. P.
    Sattar, Naveed
    Ashcroft, Darren M. M.
    Rutter, Martin K. K.
    DIABETES CARE, 2022, 45 (04) : 909 - 918
  • [17] GLP-1 Receptor Agonist Therapy With and Without SGLT2 Inhibitors in Patients With Type 2 Diabetes
    Neves, Joao Sergio
    Borges-Canha, Marta
    Vasques-Novoa, Francisco
    Green, Jennifer B.
    Leiter, Lawrence A.
    Granger, Christopher B.
    Carvalho, Davide
    Leite-Moreira, Adelino
    Hernandez, Adrian F.
    Del Prato, Stefano
    McMurray, John J. V.
    Md, Joao Pedro Ferreira
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2023, 82 (06) : 517 - 525
  • [18] Cardiovascular outcomes with GLP-1 receptor agonists vs. SGLT-2 inhibitors in patients with type 2 diabetes
    Norgaard, Caroline H.
    Starkopf, Liis
    Gerds, Thomas A.
    Vestergaard, Peter
    Bonde, Anders N.
    Fosbol, Emil
    Kober, Lars
    Wong, Nathan D.
    Torp-Pedersen, Christian
    Lee, Christina J-Y
    EUROPEAN HEART JOURNAL-CARDIOVASCULAR PHARMACOTHERAPY, 2022, 8 (06) : 549 - 556
  • [19] Cardiovascular Effectiveness of SGLT-2 Inhibitors and GLP-1 Receptor Agonists in Routine Care of Frail People with Type 2 Diabetes
    Kutz, Alexander
    Gopalakrishnan, Chandrasekar
    Kim, Dae H.
    Patorno, Elisabetta
    DIABETES, 2022, 71
  • [20] Phenotype-based targeted treatment of SGLT2 inhibitors and GLP-1 receptor agonists in type 2 diabetes
    Pedro Cardoso
    Katie G. Young
    Anand T. N. Nair
    Rhian Hopkins
    Andrew P. McGovern
    Eram Haider
    Piyumanga Karunaratne
    Louise Donnelly
    Bilal A. Mateen
    Naveed Sattar
    Rury R. Holman
    Jack Bowden
    Andrew T. Hattersley
    Ewan R. Pearson
    Angus G. Jones
    Beverley M. Shields
    Trevelyan J. McKinley
    John M. Dennis
    Diabetologia, 2024, 67 : 822 - 836
12345